Posted On: 01/04/2015 7:13:01 AM
Post# of 30066
I must say, I think this has alot of us scraching our heads. Did Nanosomix beat us to market with their 96% accurate p-tau blood test?
Why is this the first time we have heard of this?
I would have thought that Jason N would have mentioned this as he seems to be quick to point out any hurdles AMBS might face.
From the Nanosomix PR in Sept-
After re-reading the last chairmans blog after the "launch" of LYMPRO, I noticed that there was not any mention of " the first AD blood test on the market" only AMBS launches "their" first product.
http://www.thechairmansblog.com/amarantus-bio...cs-market/
I am waiting patiently to hear what CG presents on Jan 14th.
Why is this the first time we have heard of this?
I would have thought that Jason N would have mentioned this as he seems to be quick to point out any hurdles AMBS might face.
From the Nanosomix PR in Sept-
Quote:
Our first blood assay will be available this fall for researchers and pharmaceutical companies that want to use p-tau as a biomarker for drug evaluation or patient sample enrichment in their clinical trials,”
After re-reading the last chairmans blog after the "launch" of LYMPRO, I noticed that there was not any mention of " the first AD blood test on the market" only AMBS launches "their" first product.
http://www.thechairmansblog.com/amarantus-bio...cs-market/
I am waiting patiently to hear what CG presents on Jan 14th.
(0)
(0)
